PellePharm's Topical Patidegib Nears Phase III For Gorlin Syndrome
Executive Summary
Gel formulations of the hedgehog signalling inhibitor patidegib may be the long sought well-tolerated and effective therapy for basal cell carcinoma and the rare disease, Gorlin syndrome.
You may also be interested in...
Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib
Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies
BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.